Trimetazidine Hydrochloride has been proven to exert antianginal properties due to its specific metabolic mechanism of action. Trimetazidine Hydrochloride reduces the metabolic damage caused during ischemia by acting on a critical step in cardiac metabolism: fatty acid oxidation. This is made possible by the selective inhibition of an enzyme involved in fatty acid oxidation: long-chain 3-ketoacyl CoA thiolase (3-KAT). This inhibition results in a reduction in fatty acid oxidation and stimulation of glucose oxidation. Thus, the coupling of glycolysis with glucose oxidation is improved, and ATP production is further increased, while the deleterious consequences of acidosis and Ca²⁺ overload are limited.
Long-term treatment of angina pectoris.
One tablet at mealtimes in the morning and evening.
Hypersensitivity to the active substance or any of the excipients.
Rare cases of gastrointestinal disorders (nausea and vomiting).
Use in Pregnancy & Lactation
No teratogenic effects were observed in animal studies. However, in the absence of clinical data, a risk of birth defect induction cannot be excluded. Consequently, as a precaution, it is best not to prescribe the drug during pregnancy. In the absence of data on the excretion of the drug in milk, breastfeeding is not recommended during treatment.
No drug interactions have been reported. In particular, Trimetazidine can be prescribed in combination with heparin, calciparin, vitamin K antagonists, oral hypolipidemic agents, aspirin, beta-blockers, calcium inhibitors, and digitalis. (Trimetazidine has no effect on plasma levels of digoxin.)
Store at a temperature not exceeding 30ºC in a dry place. Protect from light.
Medicine: Keep out of reach of children.
